Codagenix, a spun out of the laboratory of National Academy of Science Member Eckard Wimmer at Stony Brook University is a clinical-stage synthetic biology company with a rational virus design platform for live-attenuated viral vaccines and immuno-oncology therapeutics.
The Codagenix platform is revolutionizing the vaccine and virotherapeutic development process with a synthetic biology-enabled approach that eliminates guesswork in favor of precisely designed solutions.
Codagenix was launched in 2012 as a spun out of the laboratory of National Academy of Science Member Eckard Wimmer at Stony Brook University. The company is headquartered in Farmingdale, New York.
Codagenix's breakthrough platform brings together live-attenuated virus design with cutting-edge codon deoptimization for powerful synthetic biology-based solutions to take on our biggest threats in infectious disease, cancer and animal health.
Codagenix developed CodaVax™-RSV, an intranasal, live-attenuated vaccine candidate, for the prevention of respiratory syncytial virus (RSV) disease. Codagenix is set to begin dosing in a Phase 1 trial in healthy infants and toddlers in early 2023.
Codagenix's intranasal COVID-19 vaccine candidate CoviLiv™ is currently being evaluated in the Solidarity Trial Vaccines (STV) which is supported by the World Health Organization (WHO) and the Serum Institute of India.
Codagenix is backed by The Stony Brook University Center for Biotechnology, U.S. Department of Defense, Adjuvant Capital, Euclidean Capital, Topspin Partners, the Serum Institute of India Pvt. Ltd, and others. The company closed a $25M Series B extension round on Feb 15, 2023. This brings Codagenix's total funding to $59.5M to date.